Hunan Er Kang Pharmaceutical Net Asset Quality Index
Hunan Er Kang Pharmaceutical net asset quality index. Hunan Er Kang Pharmaceutical (300267) has a Net Asset Quality Index of 87.4% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.05 Billion minus total liabilities of CN¥634.44 Million yields net assets of CN¥4.42 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 300267 net asset value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hunan Er Kang Pharmaceutical (2008–2024)
Net asset quality index of Hunan Er Kang Pharmaceutical from 2008 to 2024. This chart shows how Hunan Er Kang Pharmaceutical's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the index stands at 87.4%, representing net assets of CN¥4.42 Billion against total assets of CN¥5.05 Billion CNY. Check strategic asset allocation of Hunan Er Kang Pharmaceutical to assess the company's strategic physical and investment asset allocation.
Hunan Er Kang Pharmaceutical Net Asset Quality Index by Year (2008–2024)
Hunan Er Kang Pharmaceutical net asset quality index by year from 2008 to 2024. The table below presents the year-by-year Net Asset Quality Index for Hunan Er Kang Pharmaceutical from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300267 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 84.7% | CN¥4.40 Billion | CN¥5.20 Billion | CN¥797.54 Million | ▼ -3.1 pp |
| 2023 | 87.8% | CN¥4.81 Billion | CN¥5.48 Billion | CN¥669.05 Million | ▲ +1.5 pp |
| 2022 | 86.3% | CN¥5.05 Billion | CN¥5.86 Billion | CN¥804.57 Million | ▼ -3.5 pp |
| 2021 | 89.7% | CN¥4.87 Billion | CN¥5.43 Billion | CN¥558.28 Million | ▲ +1.2 pp |
| 2020 | 88.5% | CN¥5.79 Billion | CN¥6.55 Billion | CN¥753.22 Million | ▼ -5.8 pp |
| 2019 | 94.3% | CN¥5.79 Billion | CN¥6.14 Billion | CN¥350.72 Million | ▲ +1.1 pp |
| 2018 | 93.2% | CN¥5.64 Billion | CN¥6.05 Billion | CN¥409.39 Million | ▼ -1.4 pp |
| 2017 | 94.6% | CN¥5.41 Billion | CN¥5.72 Billion | CN¥308.37 Million | ▲ +1.8 pp |
| 2016 | 92.8% | CN¥5.24 Billion | CN¥5.65 Billion | CN¥408.94 Million | ▲ +4.1 pp |
| 2015 | 88.7% | CN¥4.26 Billion | CN¥4.80 Billion | CN¥544.10 Million | ▲ +13.1 pp |
| 2014 | 75.6% | CN¥1.68 Billion | CN¥2.22 Billion | CN¥542.64 Million | ▼ -16.6 pp |
| 2013 | 92.2% | CN¥1.33 Billion | CN¥1.45 Billion | CN¥113.01 Million | ▼ -1.9 pp |
| 2012 | 94.1% | CN¥1.16 Billion | CN¥1.24 Billion | CN¥73.32 Million | ▼ -0.1 pp |
| 2011 | 94.2% | CN¥1.06 Billion | CN¥1.13 Billion | CN¥65.90 Million | ▲ +34.4 pp |
| 2010 | 59.7% | CN¥176.62 Million | CN¥295.77 Million | CN¥119.15 Million | ▲ +0.5 pp |
| 2009 | 59.2% | CN¥110.01 Million | CN¥185.73 Million | CN¥75.72 Million | ▲ +7.7 pp |
| 2008 | 51.5% | CN¥63.01 Million | CN¥122.38 Million | CN¥59.37 Million | — |